多重成像质谱流式技术揭示p-S6是弥漫性大B细胞淋巴瘤的治疗与预后因子
研究用成像质谱流式技术检测18例弥漫性大B细胞淋巴瘤(DLBCL)样本中26种金属标记抗体的蛋白表达,识别出8种细胞类型;发现双表达(DE)组织中p-S6在B细胞和成纤维细胞中显著升高,成纤维细胞与耗竭CD8+ T细胞存在强相互作用;回顾性分析71例显示p-S6独立预测不良预后(HR 5.758,95%CI 1.297-25.558,P=.021),体外和体内实验表明成纤维细胞加速DLBCL生长,抑制p-S6可抑制增殖并与化疗协同。
要点
- DE DLBCL组织中p-S6在B细胞和成纤维细胞中显著高于非DE组织。
- p-S6独立预测DLBCL不良预后(HR 5.758,95%CI 1.297-25.558,P=.021)。
- 抑制p-S6可抑制DLBCL细胞增殖并在体内与化疗协同。
核心结论
- 研究揭示了DE DLBCL组织特异的肿瘤微环境,并确定p-S6为增强化疗疗效的有前景治疗靶点。
研究设计与样本
- 研究用成像质谱流式技术及26种金属标记抗体检测18例DLBCL患者样本的蛋白表达。
- 回顾性研究纳入71例DLBCL患者评估p-S6的预后价值。
- 体外共培养和体内实验评估成纤维细胞对DLBCL细胞生长的影响及p-S6抑制与化疗的联合效应。
- 采用bulk RNA测序鉴定mTOR/S6通路的富集。
主要发现
- 在肿瘤微环境中识别出8种细胞类型。
- DE与非DE组织中免疫细胞比例无显著差异。
- DE组织中成纤维细胞与耗竭CD8+ T细胞之间存在强相互作用。
- DE样本B细胞和成纤维细胞中p-S6水平显著高于非DE样本。
- p-S6独立预测DLBCL患者较差预后(n=71;HR 5.758;95%CI 1.297-25.558;P=.021)。
关键数值与推荐
- DE组织中p-S6在B细胞和成纤维细胞中显著高于非DE组织。
- p-S6预测不良预后的HR为5.758(95%CI 1.297-25.558,P=.021)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease characterized by distinct morphological, genetic, and clinical features. DLBCL with Myc/Bcl-2 double expression (DE) has been positively correlated with poor prognosis and a low response rate to chemotherapy. However, molecular mechanisms underlying the malignant progression of DE DLBCL and the tumor microenvironment of DE DLBCL have not been fully elucidated. In this study, we assessed protein expression in samples from 18 patients with DLBCL using imaging mass cytometry with a panel of 26 metal-tagged antibodies, identifying 8 cell types within the tumor microenvironment. Although the ratio of immune cells did not significantly differ between DE and non-DE tissues, a strong interaction between fibroblasts and exhausted CD8+ T cells was specifically observed in DE tissues. By comparing protein expression ratios between DE and non-DE tissues, we found that p-S6 levels were significantly higher in B cells and fibroblasts of DE samples than non-DE samples. In our retrospective study, p-S6 independently predicted an inferior prognosis in patients with DLBCL (n = 71; hazard ratio, 5.758; 95% confidence interval, 1.297-25.558; P = .021). In addition, coculture with fibroblasts accelerated the in vitro and in vivo growth of DLBCL cells, and enrichment of the mammalian target of rapamycin/S6 pathways was identified using bulk RNA sequencing. Conversely, specific inhibition of p-S6 suppressed DLBCL cell proliferation and exhibited synergistic effects with chemotherapy in vivo. In summary, our findings elucidated the specific tumor microenvironment in DE DLBCL tissues and identified p-S6 as a promising therapeutic target to enhance the efficacy of chemotherapy.
引用
- Zhang B, Xie Y, Shen M, et al. Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma. Blood Adv. 2025. PMID: 40238894. doi:10.1182/bloodadvances.2024015469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。